Related Experiment Videos

Ventricular cardiotrophin-1 activation precedes BNP in experimental heart failure

Michihisa Jougasaki1, Hanna Leskinen, Amy M Larsen

  • 1Institute for Clinical Research, National Hospital Kyushu Cardiovascular Center, 8-1 Shiroyama-cho, Kagoshima 892-0853, Japan. michi@qjun.hosp.go.jp

Peptides
|September 2, 2003
PubMed

Insights

Cardiotrophin-1 (CT-1) and B-type natriuretic peptide (BNP) gene expression increase in heart failure. Ventricular CT-1 activation precedes BNP activation during congestive heart failure progression in dogs.

Area of Science:

  • Cardiovascular biology
  • Molecular cardiology
  • Heart failure research

Background:

  • Cardiotrophin-1 (CT-1) and B-type natriuretic peptide (BNP) are cardiac biomarkers activated by cardiomyocyte stretch.
  • Both CT-1 and BNP gene expression are elevated in experimental and human congestive heart failure (CHF).

Purpose of the Study:

  • To investigate the cardiac gene expression patterns of CT-1 and BNP during the progression of heart failure.
  • To compare the temporal activation of CT-1 and BNP genes in the failing heart.

Main Methods:

  • Utilized Northern blot analysis to quantify CT-1 and BNP mRNA levels.
  • Examined gene expression in normal dogs, dogs with early left ventricular dysfunction (ELVD), and dogs with overt CHF (n=5 for each group).

Main Results:

  • CT-1 mRNA was detected in both atria and ventricles of normal dogs.
  • Ventricular CT-1 mRNA increased progressively from ELVD to overt CHF.
  • Ventricular BNP mRNA was minimally detected in normal and ELVD dogs, but markedly increased in overt CHF.

Conclusions:

  • Cardiac gene expression of CT-1 and BNP is differentially regulated during CHF progression.
  • Ventricular CT-1 gene activation occurs earlier than ventricular BNP gene activation in the development of CHF.

Related Concept Videos